The Silent Pandemic: From Metabolic Consequences to Exercise and Lifestyle-Driven Remodelling in Metabolic Syndrome
DOI:
https://doi.org/10.12775/QS.2026.68.74421Keywords
metabolic syndrome, metabolism, mets, visceral adiposity, insulin resistance, atherogenic dyslipidaemia, atherogenic dyslipidemia, dyslipidaemia, dyslipidemia, arterial hypertension, hypertension, lifestyle, lifestyle medicine, lifestyle modification, dietary interventionAbstract
Background: Metabolic syndrome (MetS) has emerged as one of the most critical global public health challenges of the 21st century, doubling the risk of cardiovascular events and significantly increasing all-cause mortality. Moreover, epidemiological data reflect a sharp, alarming upward trajectory in its prevalence.
Pathophysiology: This review explores the synergistic pathophysiological network of MetS. Visceral adiposity acts as the primary cellular engine, driving systemic insulin resistance. In turn, these core abnormalities trigger a cascade of downstream components, including atherogenic dyslipidaemia (the "lipid triad"), neuroendocrine-driven arterial hypertension, and systemic pro-inflammatory and pro-thrombotic states.
Diagnosis: We outline the evolution of diagnostic criteria. The consensus relies on abdominal obesity or elevated BMI as a basic criterion, combined with at least two additional factors (dysglycaemia, elevated non-HDL cholesterol, and high blood pressure).
Therapeutic Strategies: Non-pharmacological lifestyle modification — specifically the Mediterranean and DASH diets, structured aerobic and resistance training, and proper sleep hygiene — remains the absolute cornerstone of management. When lifestyle modifications fall short, modern pharmacotherapy, particularly GLP-1 receptor agonists and SGLT2 inhibitors, offers profound, synergistic cardio- and reno-protective benefits.
Conclusions: Halting the progressive multi-organ damage of metabolic syndrome requires early, holistic clinical intervention. The combination of targeted behavioural strategies and novel, organ-protective pharmacotherapies provides a powerful approach to reversing the metabolic cascade and reducing cardiovascular risk.
References
[1] Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology 2010;56:1113–32. https://doi.org/10.1016/j.jacc.2010.05.034.
[2] Drygas W, Bielecki W, Kozakiewicz K, Pajak A, Piotrowski W, Tykarski A, et al. Wieloośrodkowe Ogólnopolskie Badanie Stanu Zdrowia Ludności - WOBASZ, 2015, p. 41–55.
[3] Rajca A, Wojciechowska A, Śmigielski W, Drygas W, Piwońska A, Pająk A, et al. Increase in the prevalence of metabolic syndrome in Poland: comparison of the results of the WOBASZ (2003-2005) and WOBASZ II (2013-2014) studies. Polish Archives of Internal Medicine 2021;131:520–6. https://doi.org/10.20452/pamw.15975.
[4] Moore JX, Chaudhary N, Akinyemiju T. Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Preventing Chronic Disease 2017;14. https://doi.org/10.5888/pcd14.160287.
[5] Dhondge RH, Agrawal S, Patil R, Kadu A, Kothari M. A Comprehensive Review of Metabolic Syndrome and Its Role in Cardiovascular Disease and Type 2 Diabetes Mellitus: Mechanisms, Risk Factors, and Management. Cureus 2024;16. https://doi.org/10.7759/cureus.67428.
[6] Wan H, Wang Y, Xiang Q, Fang S, Chen Y, Chen C, et al. Associations between abdominal obesity indices and diabetic complications: Chinese visceral adiposity index and neck circumference. Cardiovascular Diabetology 2020;19. https://doi.org/10.1186/s12933-020-01095-4.
[7] Trouwborst I, Bowser SM, Goossens GH, Blaak EE. Ectopic Fat Accumulation in Distinct Insulin Resistant Phenotypes; Targets for Personalized Nutritional Interventions. Frontiers in Nutrition 2018;5. https://doi.org/10.3389/fnut.2018.00077.
[8] Jia G, Aroor AR, DeMarco VG, Martinez-Lemus LA, Meininger GA, Sowers JR. Vascular stiffness in insulin resistance and obesity. Frontiers in Physiology 2015;6. https://doi.org/10.3389/fphys.2015.00231.
[9] Demetz G, Ott I. The Interface between Inflammation and Coagulation in Cardiovascular Disease. International Journal of Inflammation 2012;2012:1–8. https://doi.org/10.1155/2012/860301.
[10] Zwick RK, Guerrero-Juarez CF, Horsley V, Plikus MV. Anatomical, physiological and functional diversity of adipose tissue. Cell Metabolism 2018;27:68–83. https://doi.org/10.1016/j.cmet.2017.12.002.
[11] Yang Y-K, Chen M, Clements RH, Abrams GA, Aprahamian CJ, Harmon CM. Human mesenteric adipose tissue plays unique role versus subcutaneous and omental fat in obesity related diabetes. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology 2008;22:531–8. https://doi.org/10.1159/000185527.
[12] Lee M-J, Kim J. The pathophysiology of visceral adipose tissues in cardiometabolic diseases. Biochemical Pharmacology 2024;222:116116–6. https://doi.org/10.1016/j.bcp.2024.116116.
[13] Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obesity Reviews 2010;11:11–8. https://doi.org/10.1111/j.1467-789x.2009.00623.x.
[14] Saponaro C, Sabatini S, Gaggini M, Carli F, Rosso C, Positano V, et al. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. Liver International 2022;42:2418–27. https://doi.org/10.1111/liv.15377.
[15] Kwok KHM, Lam KSL, Xu A. Heterogeneity of white adipose tissue: molecular basis and clinical implications. Experimental & Molecular Medicine 2016;48:e215–5. https://doi.org/10.1038/emm.2016.5.
[16] Little P, Offermanns S, Cho H, Liu Z, Yang P, Su Q, et al. Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases. iNew Medicine 2026. https://doi.org/10.1002/inm3.70028.
[17] Pliszka M, Szablewski L. Severe Insulin Resistance Syndromes: Clinical Spectrum and Management. International Journal of Molecular Sciences 2025;26:5669–9. https://doi.org/10.3390/ijms26125669.
[18] Boucher J, Kleinridders A, Kahn CR. Insulin Receptor Signaling in Normal and Insulin-Resistant States. Cold Spring Harbor Perspectives in Biology 2014;6:a009191–1. https://doi.org/10.1101/cshperspect.a009191.
[19] Thomas D D, Corkey BE, Istfan NW, Apovian CM. Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction. Journal of the Endocrine Society 2019;3:1727–47. https://doi.org/10.1210/js.2019-00065.
[20] Manjunath C, Rawal J, Irani P, Madhu K. Atherogenic dyslipidemia. Indian Journal of Endocrinology and Metabolism 2013;17:969–76. https://doi.org/10.4103/2230-8210.122600.
[21] Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495–506. https://doi.org/10.1161/01.cir.82.2.495.
[22] Kazibwe R, Schaich CL, Chevli PA, Kingsley JA, Mirzai S, Namutebi JH, et al. Lipoprotein(a), Insulin Resistance, and Cardiovascular Disease in the UK Biobank. Journal of the American Heart Association 2026;15. https://doi.org/10.1161/jaha.125.042361.
[23] Marston NA, Giugliano RP, Melloni GEM, Park J-G, Morrill V, Blazing MA, et al. Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiology 2022;7:250–6. https://doi.org/10.1001/jamacardio.2021.5083.
[24] Taskinen M-R, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 2015;239:483–95. https://doi.org/10.1016/j.atherosclerosis.2015.01.039.
[25] Bekbossynova M, Saliev T, Ivanova Razumova T, Andossova S, Kali A, Myrzakhmetova G. Small dense LDL: An underestimated driver of atherosclerosis (Review). Molecular Medicine Reports 2025;32:1–19. https://doi.org/10.3892/mmr.2025.13693.
[26] Moissl-Blanke AP, Delgado GE, Krämer BK, Siekmeier R, Duerschmied D, März W, et al. Serum Amyloid A (SAA) and Its Interaction with High-Density Lipoprotein Cholesterol (HDL-C): A Comprehensive Review. International Journal of Molecular Sciences 2025;27:241. https://doi.org/10.3390/ijms27010241.
[27] da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of Hyperinsulinemia and Insulin Resistance in Hypertension: Metabolic Syndrome Revisited. Canadian Journal of Cardiology 2020;36:671–82. https://doi.org/10.1016/j.cjca.2020.02.066.
[28] Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-Induced Hypertension. Circulation Research 2015;116:991–1006. https://doi.org/10.1161/circresaha.116.305697.
[29] Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management. Nutrition, Metabolism and Cardiovascular Diseases 2010;20:140–6. https://doi.org/10.1016/j.numecd.2009.08.006.
[30] Vanhoutte PM, Zhao Y, Xu A, Susan W.S. Leung. Thirty Years of Saying NO. Circulation Research 2016;119:375–96. https://doi.org/10.1161/circresaha.116.306531.
[31] Lacolley P, Regnault V, Laurent S. Mechanisms of Arterial Stiffening: From Mechanotransduction to Epigenetics. Arteriosclerosis, Thrombosis, and Vascular Biology 2020;40:1055–62. https://doi.org/10.1161/ATVBAHA.119.313129.
[32] Laurent S, Boutouyrie P. Arterial stiffness: a new surrogate end point for cardiovascular disease? Journal of Nephrology 2007;20 Suppl 12:S45-50.
[33] Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Frontiers in Cardiovascular Medicine 2020;7. https://doi.org/10.3389/fcvm.2020.00022.
[34] Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nature Reviews Endocrinology 2017;13:633–43. https://doi.org/10.1038/nrendo.2017.90.
[35] Achari AE, Jain SK. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. International Journal of Molecular Sciences 2017;18:1321. https://doi.org/10.3390/ijms18061321.
[36] Bou Matar D, Zhra M, Nassar WK, Altemyatt H, Naureen A, Abotouk N, et al. Adipose tissue dysfunction disrupts metabolic homeostasis: mechanisms linking fat dysregulation to disease. Frontiers in Endocrinology 2025;16. https://doi.org/10.3389/fendo.2025.1592683.
[37] Alessi M-C, Juhan-Vague I. PAI-1 and the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2006;26:2200–7. https://doi.org/10.1161/01.atv.0000242905.41404.68.
[38] Huilcaman R, Venturini W, Fuenzalida L, Cayo A, Segovia R, Valenzuela C, et al. Platelets, a Key Cell in Inflammation and Atherosclerosis Progression. Cells 2022;11:1014. https://doi.org/10.3390/cells11061014.
[39] Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.
[40] Dobrowolski P, Prejbisz A, Kuryłowicz A, Baska A, Burchardt P, Chlebus K, et al. Metabolic syndrome – A new definition and management guidelines. Archives of Medical Science 2022;18:1133–56. https://doi.org/10.5114/aoms/152921.
[41] Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Therapeutic Advances in Cardiovascular Disease 2017;11:215–25. https://doi.org/10.1177/1753944717711379.
[42] Versini M, Jeandel P-Y, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: Not a passive bystander. Autoimmunity Reviews 2014;13:981–1000. https://doi.org/10.1016/j.autrev.2014.07.001.
[43] Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care 2019;42:731–54. https://doi.org/10.2337/dci19-0014.
[44] Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. International Journal of Molecular Sciences 2022;23:786. https://doi.org/10.3390/ijms23020786.
[45] Soltani S, Shirani F, Chitsazi MJ, Salehi-Abargouei A. The effect of dietary approaches to stop hypertension (DASH) diet on weight and body composition in adults: a systematic review and meta-analysis of randomized controlled clinical trials. Obesity Reviews 2016;17:442–54. https://doi.org/10.1111/obr.12391.
[46] Shannon OM, Stephan BCM, Minihane A-M, Mathers JC, Siervo M. Nitric Oxide Boosting Effects of the Mediterranean Diet: A Potential Mechanism of Action. The Journals of Gerontology Series A, Biological Sciences and Medical Sciences 2018;73:902–4. https://doi.org/10.1093/gerona/gly087.
[47] Backes J, Anzalone D, Hilleman D, Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids in Health and Disease 2016;15. https://doi.org/10.1186/s12944-016-0286-4.
[48] Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. The New England Journal of Medicine 2001;344:3–10. https://doi.org/10.1056/NEJM200101043440101.
[49] Parada Venegas D, De la Fuente MK, Landskron G, González MJ, Quera R, Dijkstra G, et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Frontiers in Immunology 2019;10. https://doi.org/10.3389/fimmu.2019.00277.
[50] Myers J, Kokkinos P, Nyelin E. Physical Activity, Cardiorespiratory Fitness, and the Metabolic Syndrome. Nutrients 2019;11:1652. https://doi.org/10.3390/nu11071652.
[51] Richter EA, Hargreaves M. Exercise, GLUT4, and Skeletal Muscle Glucose Uptake. Physiological Reviews 2013;93:993–1017. https://doi.org/10.1152/physrev.00038.2012.
[52] Sylow L, Kleinert M, Richter EA, Jensen TE. Exercise-stimulated Glucose Uptake — Regulation and Implications for Glycaemic Control. Nature Reviews Endocrinology 2016;13:133–48. https://doi.org/10.1038/nrendo.2016.162.
[53] Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nature Reviews Immunology 2011;11:607–15. https://doi.org/10.1038/nri3041.
[54] Green DJ, Hopman MTE, Padilla J, Laughlin MH, Thijssen DHJ. Vascular Adaptation to Exercise in Humans: Role of Hemodynamic Stimuli. Physiological Reviews 2017;97:495–528. https://doi.org/10.1152/physrev.00014.2016.
[55] Laughlin MH, Davis MJ, Secher NH, Lieshout JJ, Arce‐Esquivel AA, Simmons GH, et al. Peripheral Circulation. Comprehensive Physiology 2012;2:321–447. https://doi.org/10.1002/cphy.c100048.
[56] Cornelissen VA, Smart NA. Exercise Training for Blood Pressure: A Systematic Review and Meta‐analysis. Journal of the American Heart Association 2013;2. https://doi.org/10.1161/jaha.112.004473.
[57] Leproult R, Van Cauter E. Role of sleep and sleep loss in hormonal release and metabolism. Pediatric Neuroendocrinology 2009;17:11–21. https://doi.org/10.1159/000262524.
[58] McEwen BS, Karatsoreos IN. Sleep Deprivation and Circadian Disruption Stress, Allostasis, and Allostatic Load. Sleep Medicine Clinics 2022. https://doi.org/10.1016/j.jsmc.2022.03.005.
[59] Mc P, Dr T, Cf S. Yoga, Mindfulness-Based Stress Reduction and Stress-Related Physiological Measures: A Meta-Analysis. Psychoneuroendocrinology 2017. https://pubmed.ncbi.nlm.nih.gov/28963884/ (accessed July 15, 2026).
[60] American Diabetes Association . Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care 2020;43:S98–110. https://doi.org/10.2337/dc20-s009.
[61] Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Molecular Metabolism 2021;46:101090. https://doi.org/10.1016/j.molmet.2020.101090.
[62] Wang A, Li Z, Zhuo S, Gao F, Zhang H, Zhang Z, et al. Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology. Frontiers in Cardiovascular Medicine 2022;9. https://doi.org/10.3389/fcvm.2022.857952.
[63] Libby P. Current Concepts of the Pathogenesis of the Acute Coronary Syndromes. Circulation 2001;104:365–72. https://doi.org/10.1161/01.cir.104.3.365.
[64] Scheen A. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Diabetes & Metabolism 2004;30:498–505. https://doi.org/10.1016/s1262-3636(07)70147-7.
[65] Savoia C, Schiffrin EL. Inhibition of the renin angiotensin system: implications for the endothelium. Current Diabetes Reports 2006;6:274–8. https://doi.org/10.1007/s11892-006-0060-5.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Bogumił Libura, Martyna Lazar, Łukasz Szkaradowski, Szymon Baranowski, Julia Lewańska, Krzysztof Bogdański, Zuzanna Kruszyńska, Anastasiya Aleshchyk, Michał Adamczak, Marcel Majewski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 93
Number of citations: 0
